Equities

Bachem Holding AG

Bachem Holding AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)85.70
  • Today's Change1.15 / 1.36%
  • Shares traded19.88k
  • 1 Year change-0.35%
  • Beta1.1491
Data delayed at least 15 minutes, as of Mar 28 2024 12:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.

  • Revenue in CHF (TTM)577.32m
  • Net income in CHF111.86m
  • Incorporated1971
  • Employees2.01k
  • Location
    Bachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
  • Phone+41 619352333
  • Fax+41 619352324
  • Websitehttps://www.bachem.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dottikon ES Holding AG338.23m86.17m3.32bn694.0037.993.8830.939.816.246.2424.4961.100.31350.63395.39498,861.307.997.489.588.4867.5878.9425.4822.351.65101.250.1062--26.8015.0947.9427.7030.78--
Siegfried Holding AG1.27bn112.06m4.10bn3.93k34.534.6021.113.2226.2826.28298.23197.490.69582.273.14323,288.606.176.517.677.9825.2023.248.869.061.397.930.346815.263.419.87-28.1618.3417.956.72
Krka d.d. Novo Mesto1.77bn307.21m4.16bn11.78k12.771.8510.032.3510.1410.1458.3670.020.66271.353.96153,343.9011.5112.6413.7515.1256.8457.2917.3718.712.5419.990.0055--5.186.28-13.5812.458.35--
Laboratorios Farmaceuticos ROVI SA811.71m166.68m4.26bn2.11k25.177.7522.775.253.203.2015.5810.410.98831.045.13392,946.0020.2918.9028.8825.5859.3559.8220.5320.130.8575--0.107533.601.4422.30-14.6956.9315.8469.11
Richter Gedeon Vegyeszeti Gyar Nyrt2.00bn393.72m4.28bn12.17k10.801.508.172.14857.81857.794,349.056,173.080.59311.714.08--11.8311.6413.3913.2864.7558.1819.9518.933.127.490.015939.700.299312.57-6.0535.0615.5933.38
Hikma Pharmaceuticals Plc2.60bn171.74m4.77bn8.97k27.802.3911.691.830.67650.676510.237.870.62841.763.67253,693.804.208.195.7211.3048.9450.296.6813.770.90297.680.350336.7114.226.731.06-7.597.974.54
Orion Oyj1.16bn212.15m4.77bn3.63k22.285.4418.464.091.551.558.496.340.80881.575.56327,588.1014.7219.4718.0324.1655.3059.3818.2020.711.7594.790.183591.83-11.264.01-37.971.8911.821.55
DiaSorin SpA-97.85bn-97.85bn4.87bn3.28k--------------------------13.14--14.79--67.40--23.33------23.899.9816.38-22.5311.4921.765.29
Grifols SA6.45bn58.04m4.98bn23.74k92.040.96688.180.77230.09010.09019.808.580.30681.239.86277,627.000.84082.391.063.0437.8440.262.747.541.291.560.5593--8.718.00-71.52-36.98-0.8127--
Zealand Pharma A/S44.98m-92.35m5.60bn253.00--24.98--124.49-12.57-12.576.0127.280.19484.16289.881,354,889.00-39.99-42.74-46.30-50.2487.3996.13-205.30-464.666.23--0.0696--229.6555.2727.12--42.53--
BACHEM HOLDING AG577.32m111.86m6.34bn2.01k56.404.8040.3710.981.501.507.7317.610.37651.233.33287,794.607.298.858.1710.2830.6531.6319.3819.743.0429.800.000355.378.5715.3711.1019.1250.887.78
Croda International Plc1.94bn195.34m7.74bn5.85k39.682.8822.724.001.221.2212.1216.850.47132.404.39289,559.104.7910.805.4212.5143.0846.4110.1618.641.7717.070.230743.44-18.904.09-73.66-6.4212.784.11
Swedish Orphan Biovitrum AB (publ)1.88bn205.17m8.22bn1.79k36.792.7317.204.367.407.4068.6599.680.34971.384.25--3.815.935.207.6077.5877.4110.8816.610.46074.040.37690.0017.7419.34-8.68-0.072953.61--
Qiagen NV1.78bn308.50m8.55bn5.97k27.932.4817.314.821.411.418.1215.890.31691.935.38304,232.905.505.416.606.5362.7764.6517.3716.351.62--0.2839---8.235.53-19.3512.381.55--
Ipsen SA3.24bn603.86m8.96bn5.07k14.772.3612.892.777.397.7239.6646.290.5541.995.23--10.489.7113.9313.3382.7282.7618.9116.020.98930.430.110619.874.757.084.039.75-8.653.71
Data as of Mar 28 2024. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

16.77%Per cent of shares held by top holders
HolderShares% Held
VV Verm�gensverwaltung AGas of 29 Dec 20233.55m4.73%
Capital Research & Management Co. (World Investors)as of 31 Dec 20233.23m4.31%
The Vanguard Group, Inc.as of 07 Mar 20241.10m1.46%
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023924.17k1.23%
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 2024852.03k1.14%
Norges Bank Investment Managementas of 31 Dec 2023719.50k0.96%
UBS Asset Management Switzerland AGas of 05 Mar 2024634.34k0.85%
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024541.99k0.72%
Premier Fund Managers Ltd.as of 30 Nov 2023516.18k0.69%
BlackRock Fund Advisorsas of 07 Mar 2024511.25k0.68%
More ▼
Data from 29 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.